To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

Also called NCT06481085

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 324 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06481085
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06481085. Randomized; quadruple masking; primary purpose treatment. Start 2024-06-27 (actual); primary completion 2025-05-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Intervention (Drug)
HDM1002 50 mg
Intervention (Drug)
HDM1002 100 mg
Intervention (Drug)
HDM1002 200 mg
Intervention (Drug)
HDM1002 400 mg
Intervention (Drug)
HDM1002 200 mg BID
Intervention (Drug)
Placebo
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06481085
Content hash
26da962f7c54ccd9b234ed19b3ba28962ca76557db331f767fd1cefe5485ff09